CALITHERA BIOSCIENCES INC (CALA) Stock Price, Quote, News and Overview
NASDAQ:CALA - Nasdaq - US13089P5070 - Common Stock - Currency: USD
CALA Quote, Performance and Key Statistics
0.3651
-0.04 (-10.95%)
The current stock price of CALA is 0.3651 USD. In the past month the price decreased by -88.15%. In the past year, price decreased by -96.7%.
CALA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About CALA
Company Profile
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The firm is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The firm is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The firm is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The firm's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.
Company Info
CALITHERA BIOSCIENCES INC
343 Oyster Point Blvd #200
South San Francisco CALIFORNIA 94080 US
CEO: Susan M. Molineaux
Employees: 63
Company Website: http://www.calithera.com/
Phone: 16508701000.0
CALITHERA BIOSCIENCES INC / CALA FAQ
What is the stock price of CALITHERA BIOSCIENCES INC today?
The current stock price of CALA is 0.3651 USD. The price decreased by -10.95% in the last trading session.
What is the ticker symbol for CALITHERA BIOSCIENCES INC stock?
The exchange symbol of CALITHERA BIOSCIENCES INC is CALA and it is listed on the Nasdaq exchange.
On which exchange is CALA stock listed?
CALA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CALITHERA BIOSCIENCES INC stock?
10 analysts have analysed CALA and the average price target is 5.1 USD. This implies a price increase of 1296.88% is expected in the next year compared to the current price of 0.3651. Check the CALITHERA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CALITHERA BIOSCIENCES INC worth?
CALITHERA BIOSCIENCES INC (CALA) has a market capitalization of 1.78M USD. This makes CALA a Nano Cap stock.
How many employees does CALITHERA BIOSCIENCES INC have?
CALITHERA BIOSCIENCES INC (CALA) currently has 63 employees.
Is CALITHERA BIOSCIENCES INC (CALA) expected to grow?
The Revenue of CALITHERA BIOSCIENCES INC (CALA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CALA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CALITHERA BIOSCIENCES INC (CALA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CALA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CALA, evaluating the profitability, health, valuation and growth aspects
- CALITHERA BIOSCIENCES INC (CALA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CALITHERA BIOSCIENCES INC (CALA) Sales and EPS estimates to see what analysts future expectations are.
- CALITHERA BIOSCIENCES INC (CALA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CALITHERA BIOSCIENCES INC (CALA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CALITHERA BIOSCIENCES INC (CALA) Stock Chart to make your own analysis
- CALITHERA BIOSCIENCES INC (CALA) Latest news and press-releases to stay up to date.
Does CALITHERA BIOSCIENCES INC (CALA) stock pay dividends?
CALA does not pay a dividend.
When does CALITHERA BIOSCIENCES INC (CALA) report earnings?
CALITHERA BIOSCIENCES INC (CALA) will report earnings on 2023-03-29, after the market close.
What is the Price/Earnings (PE) ratio of CALITHERA BIOSCIENCES INC (CALA)?
CALITHERA BIOSCIENCES INC (CALA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12).
What is the Short Interest ratio of CALITHERA BIOSCIENCES INC (CALA) stock?
The outstanding short interest for CALITHERA BIOSCIENCES INC (CALA) is 0.41% of its float. Check the ownership tab for more information on the CALA short interest.
CALA Technical Analysis
CALA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CALA. CALA may be in some trouble as it scores bad on both profitability and health.
CALA Financial Highlights
Over the last trailing twelve months CALA reported a non-GAAP Earnings per Share(EPS) of -12. The EPS increased by 36.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CALA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to CALA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 69.34% and a revenue growth -100% for CALA